In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival-Reference-Cited by-同舟云学术

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

Published:2011-03-25 Issue:3 Volume:224 Page:389-400
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Ladoire Sylvain,Mignot Grégoire,Dabakuyo Sandrine,Arnould Laurent,Apetoh Lionel,Rébé Cedric,Coudert Bruno,Martin Francois,Bizollon Marie Hélène,Vanoli André,Coutant Charles,Fumoleau Pierre,Bonnetain Franck,Ghiringhelli François

Funder

Fondation de France

Ligue Contre le Cancer

Association pour la Recherche sur le Cancer

INSERM

INCA

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.2866/fullpdf

Reference42 articles.

1. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;Kuerer;J Clin Oncol,1999

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer;Buzdar;J Clin Oncol,2005

5. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study;Untch;J Clin Oncol,2010

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?;ESMO Open;2024-09

2. A review concerning the breast cancer-related tumour microenvironment;Critical Reviews in Oncology/Hematology;2024-07

3. Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer;Journal of Surgical Oncology;2024-06-06

4. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade;npj Breast Cancer;2024-04-18

5. Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer;EMBO Molecular Medicine;2024-03-13